Spyre Therapeutics, Inc.
SYRE
$14.43
$0.302.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 688.00K | 886.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 688.00K | 886.00K |
| Cost of Revenue | 197.72M | 118.97M | 118.97M | 118.97M | 97.82M |
| Gross Profit | -197.72M | -118.97M | -118.97M | -118.29M | -96.94M |
| SG&A Expenses | 45.78M | 49.08M | 47.01M | 42.07M | 34.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 208.57M | 195.07M | 172.92M | 147.27M | 118.50M |
| Operating Income | -208.57M | -195.07M | -172.92M | -146.58M | -117.61M |
| Income Before Tax | -207.97M | -214.85M | -185.95M | -364.18M | -338.82M |
| Income Tax Expenses | 51.00K | 50.00K | 35.00K | 42.00K | -26.00K |
| Earnings from Continuing Operations | -208.02 | -214.90 | -185.98 | -364.23 | -338.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.02M | -214.90M | -185.98M | -364.23M | -338.79M |
| EBIT | -208.57M | -195.07M | -172.92M | -146.58M | -117.61M |
| EBITDA | -207.82M | -194.51M | -172.55M | -146.03M | -116.87M |
| EPS Basic | -3.38 | 8.16 | 0.18 | -55.75 | -59.44 |
| Normalized Basic EPS | -2.77 | -4.74 | -11.90 | -23.73 | -26.04 |
| EPS Diluted | -3.38 | 8.16 | 0.18 | -55.75 | -59.44 |
| Normalized Diluted EPS | -2.77 | -4.74 | -11.90 | -23.73 | -26.04 |
| Average Basic Shares Outstanding | 187.98M | 148.33M | 101.73M | 60.24M | 27.49M |
| Average Diluted Shares Outstanding | 187.98M | 148.33M | 101.73M | 60.24M | 27.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |